Every story we've covered involving analyst-rating.
Citi analysts have advised investors to sell shares of Moderna, arguing that the company's revenue and profit projections do not support the large increase already priced into its stock. The recommendation follows a more than 600% rise in Moderna's share price.
No stories here yet.